ADVAIR DISKUS 500/50 Drug Patent Profile

When do Advair Diskus 500/50 patents expire, and what generic alternatives are available?

Advair Diskus 500/50 is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in ADVAIR DISKUS 500/50 is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Advair Diskus 500/50

A generic version of ADVAIR DISKUS 500/50 was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17^th, 2020.

Summary for ADVAIR DISKUS 500/50

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	59
DailyMed Link:	ADVAIR DISKUS 500/50 at DailyMed

Recent Clinical Trials for ADVAIR DISKUS 500/50

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Becro Ltd.	Phase 3
Teva Pharmaceuticals USA	Phase 3
Respirent Pharmaceuticals Co Ltd.	Phase 1

See all ADVAIR DISKUS 500/50 clinical trials

Pharmacology for ADVAIR DISKUS 500/50

Drug Class	Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ADVAIR DISKUS 500/50

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ADVAIR DISKUS 500/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-003	Aug 24, 2000	AB	RX	Yes	Yes

Expired US Patents for ADVAIR DISKUS 500/50

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp Ltd	ADVAIR DISKUS 500/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-003	Aug 24, 2000

EU/EMA Drug Approvals for ADVAIR DISKUS 500/50

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Airexar Spiromax	salmeterol xinafoate, fluticasone propionate	EMEA/H/C/004267Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1	Withdrawn	no	no	no	2016-08-18

International Patents for ADVAIR DISKUS 500/50

See the table below for patents covering ADVAIR DISKUS 500/50 around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	97396
Ireland	810282
United Kingdom	8920235
Japan	H03858

Supplementary Protection Certificates for ADVAIR DISKUS 500/50

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
0416951	C990012	Netherlands		PRODUCT NAME: SALMETEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN FLUTICASONPROPIONAAT,IN HET BIJZONDER SALMETEROLXINAFOAAT EN FLUTICASONPROPIONAAT; NATL REGISTRATION NO/DATE: RVG 23529 - RVG 23534 19990112; FIRST REGISTRATION: SE 14591 - 14596 19980907

Advair Diskus 500/50: Market dynamics and financial trajectory

Last updated: April 25, 2026

What is Advair Diskus 500/50 and how does it sell?

Advair Diskus 500/50 (fluticasone propionate 500 mcg plus salmeterol xinafoate 50 mcg) is an inhaled fixed-dose combination for chronic obstructive pulmonary disease (COPD) and asthma management, marketed in a dry powder inhaler (DPI) format. In the U.S., “Advair” is the dominant brand family for fluticasone/salmeterol combinations and has historically sold at scale due to clinician familiarity, payer coverage, and entrenched patient maintenance use.

A critical commercial point: the Advair Diskus 500/50 strength is a high-dose option within the Advair portfolio. Its demand is driven less by new-to-brand adoption and more by:

• Patient step-up from lower strengths to higher-dose maintenance
• Long-cycle persistence in chronic respiratory disease populations
• Formulary positioning relative to competing inhaled corticosteroid/long-acting beta agonist (ICS/LABA) products

How has the market evolved versus key respiratory competitors?

Advair has faced sustained competitive pressure from other ICS/LABA combinations and from competitor inhaler platforms that have expanded payer formularies and patient switching.

Competitive set (U.S. commercial reality)

While Advair is a category leader historically, it competes against major branded and authorized generics in ICS/LABA:

• Breo Ellipta (fluticasone furoate/vilanterol, GSK)
• Symbicort (budesonide/formoterol, AstraZeneca)
• Trelegy Ellipta (ICS/LABA/LAMA triple therapy, GSK) for COPD treatment patterns that favor triple therapy escalation
• Generic ICS/LABA products (multiple entrants across strengths and device formats)

Market dynamics that matter for financial trajectory

1. Dose migration within the Advair family

   • Higher strengths (like 500/50) can hold better than mid/low strengths if prescribers use stepwise escalation for uncontrolled disease.
   • If payers tighten prior authorization, the net effect typically reduces volume growth and shifts demand to lower-cost strengths or preferred alternatives.

2. Treatment pattern shift toward triple therapy in COPD

   • COPD management has moved toward earlier or more frequent use of triple therapy (ICS/LABA/LAMA) in appropriate patients.
   • That reduces the long-term addressable base for ICS/LABA-only maintenance unless patients fail or do not tolerate triple therapy.

3. Device substitution and formulary incentives

   • Ellipta-branded platforms (Breo and Trelegy) have benefited from device familiarity, payer contracts, and broad product-line coverage.
   • DPI versus other inhaler platforms influences both patient preference and payer guidance, affecting the mix across strengths.

What drives the “500/50” specific demand profile?

Advair Diskus 500/50 is not a mass-market starter product. Its commercial engine is maintenance disease management where prescribers choose higher ICS exposure.

Demand drivers

• Clinical step-up behavior: Patients with persistent symptoms on lower fluticasone/salmeterol strengths can be advanced to 500/50.
• Physician familiarity: Long-standing prescribing patterns keep “Advair” in the rotation even as newer inhalers expand.
• Payer coverage design: High-dose strengths face higher scrutiny for medical necessity and copay design.

Volume sensitivity

• The product’s high-dose positioning generally makes it less sensitive to initial category awareness and more sensitive to:
  • formulary tiering,
  • prior authorization criteria,
  • and switching pressure from other ICS/LABA or triple therapy.

How does patent and exclusivity status impact revenue?

Advair faces the normal post-exclusivity commercial reality for legacy respiratory brands: generic penetration in the broader fluticasone/salmeterol space has compressed price and share over time.

Two factors typically determine the speed and magnitude of financial erosion for a specific strength:

• When generics gained approval for relevant strengths and devices
• How quickly payers adopted generics via formulary tiering and interchange policies

What is the financial trajectory for Advair Diskus 500/50?

The available evidence supports a broader brand-level trajectory for Advair as a legacy respiratory franchise: market growth is limited post-launch maturity; revenue declines (or flat-to-declining growth) are driven by generic competition, price compression, and formulation/device substitution.

However, public disclosures rarely isolate “Advair Diskus 500/50” as a standalone revenue line item in plain text. Most company reporting groups “Advair” and other respiratory SKUs at broader granularity. Without a source that breaks out the 500/50 strength’s unit or revenue performance, the only defensible conclusion is directional: the product is inside a mature, price-declining, competition-exposed branded franchise.

Financial trajectory (directional, not strength-isolated)

• Mature branded phase: steady but growth-limited demand from maintenance patients
• Post-exclusivity pressure: accelerated unit and net price declines as generics entered the fluticasone/salmeterol market
• Mix effects: potential mix shifts within Advair strengths, but not enough to offset broader erosion once payer switching accelerates

Market dynamics summary: what will happen to sales near term?

Net forces acting on Advair Diskus 500/50

• Downward forces (typical):

  • generic substitution and formulary displacement
  • triple therapy switching in COPD
  • payer step edits for high-dose inhaled steroid products

• Stabilizing forces (typical):

  • entrenched maintenance patient base
  • clinician and patient familiarity with fluticasone/salmeterol regimens
  • potential persistence among patients who maintain on stable regimens

Near-term commercial expectation

The trajectory is expected to remain declining or range-bound relative to category growth, with performance more dependent on payer contracting and switching than on brand expansion.

Competitive pricing and contracting: why net revenue compresses

Brand inhalers commonly experience net revenue compression from:

• higher discounting as generics gain penetration
• payer-directed preferred products
• channel restocking cycles and inventory dynamics around generic rollouts

For Advair Diskus 500/50, those mechanisms generally map to:

• lower realized net price after generic competitive pressure
• reduced share in markets with aggressive formulary management
• potential brand mix shifting toward strengths with relatively better formulary positioning

Regulatory and labeling considerations that affect access

Access is shaped by:

• COPD and asthma guideline updates
• payer medical policies
• inhaler device coverage constraints

Advair remains within established guideline frameworks, but payer coverage often becomes more restrictive for high-dose strengths once lower-cost alternatives are available.

Key Takeaways

• Advair Diskus 500/50 is a high-dose ICS/LABA maintenance option whose demand depends on chronic persistence and step-up prescribing rather than new-brand adoption.
• The product’s financial path is dominated by mature-market dynamics: generic substitution in fluticasone/salmeterol and payer switching, with additional downward pressure from COPD triple-therapy adoption patterns.
• Strength-level financial performance is rarely disclosed publicly; the defensible conclusion is that Advair’s brand franchise has moved into a price-compressed, competition-exposed trajectory in which 500/50 mix effects typically do not reverse the broader decline.

FAQs

1. Is Advair Diskus 500/50 a COPD or asthma product?
   It is used for maintenance treatment in COPD and asthma, depending on patient indication and local prescribing practices.

2. What drives demand for the 500/50 strength specifically?
   Step-up maintenance from lower fluticasone/salmeterol strengths, persistence in chronic disease, and payer coverage for high-dose inhaled steroid regimens.

3. What are the main competitive threats to Advair Diskus?
   Other ICS/LABA products and COPD triple therapy (ICS/LABA/LAMA), plus generic fluticasone/salmeterol competition.

4. Why does net revenue tend to fall after exclusivity ends?
   Payer formulary placement shifts toward generics, realized net price declines due to discounting and competition, and share erodes as substitution increases.

5. Is there public reporting that isolates “Advair Diskus 500/50” revenue?
   Public company reporting typically aggregates Advair franchise results rather than disclosing strength-level revenue.

---

References

[1] FDA. Advair Diskus prescribing information (fluticasone propionate and salmeterol xinafoate) for inhalation powder. U.S. Food and Drug Administration.
[2] GlobalData. Drug and market access profiles for Advair and fluticasone/salmeterol products (company market intelligence).
[3] GSK (GlaxoSmithKline). Annual reports and investor materials discussing Advair franchise performance and respiratory portfolio dynamics.